US Drug Pricing Debate Enters Critical Phase: Two Visions For 2021
If the Senate's bipartisan price reform proposal is enacted into law this year, the drug pricing agenda for the next Administration will likely be set: implementing a host of changes to Medicare Part B, Part D and Medicaid. But if it fails, then more direct price negotiation measures will likely be the new starting point.
You may also be interested in...
Upcoming transition in HHS drug pricing policy staff reinforces the Trump Administration's shift away from the 2018 "Blueprint” and towards engaging with bipartisan Congressional legislation – and spotlighting executive action as coming from the White House in the context of the upcoming Presidential campaign.
President Trump isn’t going to let the Democrats own the drug pricing debate heading into the 2020 elections, so biopharma companies can look forward to many more headlines like the importation announcement on 31 July. When will it end?
Senate Finance drug pricing bill is moving forward, with two critical amendments defeated by 14-14 tie votes. One would have stripped the inflation penalty from the bill, which probably would have killed any bipartisan momentum. The second targeted the Medicare Part B International Pricing Index and was defeated by a truly surprising set of votes.